InfuSystem reports record Q2 revenue of $31.7M (+17% YoY), net income $0.4M, raises FY guidance

InfuSystem Holdings, Inc

2023-Q2 EPS reported $0.01 revenue$62,105,000

Net revenue record $31.7M (+17% YoY); Patient Services $19.3M (+12%), Device Solutions $12.4M (+27%).
Net income $0.4M ($0.02 diluted EPS) vs net loss -$0.2M (-$0.01) in Q2 2022.
Adjusted EBITDA $5.8M (18.2% margin), up 4% YoY and 36% sequentially.
FY 2023 guidance raised: revenue growth above prior 8-10% range; Adj EBITDA margin 17-18%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

InfuSystem Holdings, Inc reported second quarter ended June 30, 2023 results: revenue $31.7 million, net income $0.4 million, or $0.02 per diluted share, EPS $0.02 per diluted share. Guidance raised.

Period: second quarter ended June 30, 2023
Revenue: $31.7 million
Net income: $0.4 million, or $0.02 per diluted share
EPS: $0.02 per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

InfuSystem Reports Second Quarter 2023 Financial Results Record Net Revenues of $31.7 million Representing 17% Growth From the Prior Year Rochester Hills, Michigan, August 3, 2023 – InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the second quarter ended June 30, 2023.

View on SEC.gov

50 earnings releases filed in the last 30 days. Browse all earnings releases →

InfuSystem Holdings, Inc filing history →

Source: SEC EDGAR

accession 0001628280-23-026963

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.